Quick answer: Functional hematology goes beyond the standard CBC to identify the root causes of anemia — distinguishing between iron deficiency anemia (the world’s most common nutritional deficiency, affecting 2 billion people globally), B12 deficiency anemia, folate deficiency, anemia of chronic disease/inflammation, and hemolytic anemia. Each has a distinct functional mechanism requiring different interventions. Ferritin <30 ng/mL occurs in 40% of premenopausal women and impairs cognitive function, exercise capacity, thyroid function, and neurotransmitter synthesis before hemoglobin drops. Vitamin B12 deficiency — affecting 40% of adults over 60 and exacerbated by metformin and PPIs — causes irreversible neurological damage if untreated for more than 12 months.
Iron Deficiency: The Most Prevalent Nutritional Deficiency in the World
Iron deficiency exists on a spectrum: iron depletion (low ferritin, normal hemoglobin) → iron-deficient erythropoiesis (low ferritin, low transferrin saturation, rising RBC production markers) → iron deficiency anemia (low ferritin, low hemoglobin, microcytic hypochromic red cells). Conventional medicine typically treats only the anemia stage. Functional medicine treats the depletion stage — because the symptomatic burden of low ferritin (fatigue, brain fog, exercise intolerance, restless legs, hair loss, cold intolerance) is identical to iron deficiency anemia, yet frequently missed by practitioners who check only hemoglobin.
Serum ferritin is the gold standard for iron stores, but has critical interpretation caveats. Ferritin is an acute-phase reactant — it rises with inflammation, infection, liver disease, and metabolic syndrome. A “normal” ferritin in a woman with chronic inflammation may actually represent iron deficiency masked by inflammatory elevation. The correct interpretation requires: ferritin + hs-CRP (if CRP elevated, ferritin is unreliable alone) + transferrin saturation + serum iron + TIBC. True iron deficiency: ferritin <30 ng/mL OR transferrin saturation <20% with elevated TIBC. Functional optimal ferritin for symptom resolution: >50 ng/mL for most patients; >70–100 ng/mL for athletes and those with cognitive symptoms.
Root causes of iron deficiency requiring investigation: (1) Inadequate intake — vegetarian/vegan diets (non-heme iron 5–12% absorbed vs heme iron 15–35%); (2) Malabsorption — achlorhydria (PPIs reduce gastric acid required for ferric → ferrous iron conversion, affecting 30–50% of those on long-term PPIs), Helicobacter pylori gastritis (H. pylori competes for iron and reduces gastric acid), celiac disease, small intestinal dysbiosis/SIBO; (3) Blood loss — menorrhagia (most common cause in premenopausal women; ferritin <15 ng/mL in 30% of women with heavy periods), GI bleeding (peptic ulcer, colorectal cancer — must exclude in adults over 50 with new iron deficiency); (4) Inflammation — hepcidin excess in chronic inflammatory states sequesters iron in macrophages, blocking absorption and utilization.
Iron supplementation strategy: ferrous glycinate (bisglycinate) — the most bioavailable and best-tolerated form, with 25–90 mg elemental iron per capsule — is superior to ferrous sulfate (causes significant GI side effects in 40% of users). Liquid ferric iron (Floradix) is effective and gentle for women and children. Key co-factors: vitamin C 500 mg with each iron dose (converts ferric to ferrous, enhancing absorption 2–4 fold); avoid simultaneous calcium, tannins (tea, coffee), and phytates (whole grains) which impair absorption. Alternate-day dosing (vs daily) has been shown in Moretti 2015 (Blood) to increase net iron absorption by 50% vs daily dosing by reducing hepcidin suppression between doses. Recheck ferritin 6–8 weeks after initiating treatment.
Vitamin B12 Deficiency: Neurological Consequences and Hidden Causes
Vitamin B12 (cobalamin) deficiency is the second most common nutritional deficiency causing anemia globally. Its neurological consequences — subacute combined degeneration of the spinal cord (demyelination of dorsal and lateral columns), peripheral neuropathy, cognitive decline, and psychiatric symptoms — can be irreversible if deficiency persists beyond 12 months. The tragic aspect: neurological damage from B12 deficiency often precedes any hematological changes. Patients with macrocytic anemia who have also started folate supplements (which corrects the anemia) may have masked B12 deficiency neurological progression.
Subar 2010 (American Journal of Clinical Nutrition) documented that serum B12 levels in the conventional “normal” range (200–900 pg/mL) are unreliable: 40% of people with B12 in the 200–400 pg/mL range have functional B12 deficiency — detectable by elevated methylmalonic acid (MMA) and/or homocysteine. MMA is the most sensitive and specific functional B12 marker — it accumulates when B12-dependent methylmalonyl-CoA mutase is impaired. Homocysteine elevation reflects both B12 and folate deficiency (both required for homocysteine methylation). Functional B12 testing should always include serum B12 + MMA + homocysteine for complete assessment.
Root causes of B12 deficiency: (1) Metformin — depletes B12 by reducing ileal calcium-dependent membrane receptor binding of the intrinsic factor-B12 complex. Metformin reduces B12 levels in 30% of users at standard doses, with 9% developing frank deficiency within 5 years (de Jager 2010, BMJ). Every patient on metformin should have B12 and MMA checked annually; (2) PPIs and H2 blockers — reduce gastric acid required to release protein-bound B12 from food; (3) Pernicious anemia — autoimmune anti-intrinsic factor and anti-parietal cell antibodies; (4) Vegetarian/vegan diet — B12 is found exclusively in animal products; algae and fermented foods have unreliable bioavailability; (5) Gut dysbiosis/SIBO — bacterial competition and reduced ileal absorption; (6) Aging — gastric atrophy in 30–50% of adults over 70 reduces intrinsic factor and acid production; (7) MTHFR variants — impair the conversion of methylcobalamin to the active form needed for methionine synthesis.
B12 supplementation forms: methylcobalamin (methyl-B12) and adenosylcobalamin are the active coenzyme forms — superior to cyanocobalamin (which requires two conversion steps and is poorly retained in MTHFR variants). Oral high-dose B12 (1,000–2,000 mcg/day methylcobalamin sublingually) is effective even in pernicious anemia via passive diffusion, though traditional teaching favors intramuscular injections. For confirmed deficiency: 1,000 mcg IM methylcobalamin or hydroxocobalamin weekly for 4–8 weeks, then monthly for maintenance. Recheck MMA and homocysteine (not just serum B12, which rises with all forms including inactive analogues) to confirm functional correction.
Anemia of Chronic Disease / Inflammation: The Hepcidin-Iron Axis
Anemia of chronic disease (ACD) — now more accurately termed anemia of inflammation — is the second most common cause of anemia globally (after iron deficiency) and the most common anemia in hospitalized patients. The mechanism is well-characterized: inflammatory cytokines (IL-6, TNF-α, IL-1β) upregulate hepatic hepcidin production. Hepcidin binds and degrades ferroportin — the iron export channel on macrophages, hepatocytes, and gut enterocytes — trapping iron intracellularly and reducing both intestinal absorption and mobilization of iron stores. The result: functional iron deficiency (iron locked in storage, unavailable for erythropoiesis) combined with reduced RBC lifespan and suppressed EPO response.
ACD occurs in virtually all chronic inflammatory conditions: rheumatoid arthritis, IBD, CKD, obesity, heart failure, malignancy, chronic infections, and even depression. The ferritin paradox applies here: ferritin can be normal or elevated in ACD (reflecting inflammatory upregulation) while true iron availability for red cell production is severely impaired. Key distinguishing labs: ferritin elevated (>100 ng/mL in pure ACD) with low transferrin saturation (<20%), low serum iron, and normal or elevated TIBC is ACD; low ferritin with elevated TIBC is iron deficiency anemia. Soluble transferrin receptor (sTfR):ferritin ratio can distinguish iron deficiency from ACD in combined presentations.
Functional treatment of ACD focuses on the underlying inflammatory driver rather than iron supplementation (which is ineffective and potentially harmful when iron is already trapped in macrophages generating reactive oxygen species). Interventions that reduce IL-6 and hepcidin: omega-3 3–4 g/day (reduces IL-6 and TNF-α); curcumin 1–3 g/day bioavailable form; gut microbiome restoration (reducing LPS-driven TLR4 activation and downstream IL-6); NAC 600 mg BID (antioxidant support reducing inflammatory signaling); and addressing the primary inflammatory source (IBD, RA, infections).
Folate Deficiency: MTHFR, Neural Tube Defects, and Cardiovascular Risk
Folate deficiency produces megaloblastic anemia (macrocytic anemia with hypersegmented neutrophils) — identical to B12 deficiency in blood picture but with different neurological consequences (folate deficiency does not cause the characteristic subacute combined degeneration of B12 deficiency). Differentiation requires MMA testing: elevated in B12 deficiency, normal in pure folate deficiency.
MTHFR C677T polymorphism — present in 10–15% of Northern European populations as homozygous TT and 40–50% as heterozygous CT — reduces the MTHFR enzyme’s ability to convert 5,10-methylenetetrahydrofolate to the active 5-methyltetrahydrofolate (5-MTHF) by 30–65%. This impairs methylation capacity, elevates homocysteine (dose-dependently increasing cardiovascular risk — Clarke 2002 JAMA demonstrated 20% CVD risk increase per 5 μmol/L homocysteine rise), and reduces glutathione production. Importantly, MTHFR homozygous individuals cannot efficiently convert synthetic folic acid to active 5-MTHF, and may accumulate unmetabolized folic acid that paradoxically impairs folate receptor function.
Dietary sources: leafy green vegetables (spinach, kale, asparagus), legumes, liver. For supplementation: L-methylfolate (5-MTHF, as Metafolin or Quatrefolic) bypasses MTHFR entirely and is the preferred form for all patients, but especially MTHFR variants. Dose: 400–800 mcg/day prophylactic; 1,000–5,000 mcg/day for therapeutic homocysteine reduction. Combined with methylcobalamin (B12) and P-5-P (active B6) for comprehensive methylation support and homocysteine normalization (target <8 μmol/L functional; conventional upper limit is 15 μmol/L).
Hemolytic Anemia and Oxidative Stress: G6PD, Autoimmune, and Functional Evaluation
Hemolytic anemias — where red blood cells are destroyed faster than production compensates — include hereditary (G6PD deficiency, hereditary spherocytosis, sickle cell) and acquired (autoimmune hemolytic anemia, drug-induced, microangiopathic) causes. G6PD deficiency — the world’s most common enzyme deficiency (400 million affected) — impairs the pentose phosphate pathway that regenerates NADPH, leaving red cells vulnerable to oxidative hemolysis from: infections, oxidant drugs (dapsone, antimalarials, nitrofurantoin), and dietary triggers (fava beans, large doses of vitamin C).
Autoimmune hemolytic anemia (AIHA) — warm or cold antibody types — represents immune dysregulation attacking red cell surface antigens. Functional triggers: Mycoplasma pneumoniae infection (cold agglutinin AIHA), Epstein-Barr virus, systemic lupus, or idiopathic. The functional workup includes direct antiglobulin test (DAT/Coombs), cold agglutinin titer, and assessment for underlying autoimmune disease. Functional support alongside conventional therapy: antioxidant support to reduce oxidative hemolysis burden (vitamin E 400 IU/day, NAC 600 mg BID), immune modulation for AIHA (vitamin D, omega-3, gut restoration to reduce Th1/Th17 overactivation), and avoidance of known triggers.
Functional Hematology Testing: What to Order and How to Interpret
A complete functional hematology panel goes beyond the standard CBC with differential. For any patient with fatigue, exercise intolerance, cognitive impairment, or suspected anemia: (1) CBC with differential and reticulocyte count; (2) Iron panel: serum iron, TIBC, transferrin saturation, serum ferritin; (3) Vitamin B12 (serum) + methylmalonic acid (MMA) + homocysteine; (4) 25-OH vitamin D (deficiency impairs EPO production and RBC maturation); (5) hs-CRP (to contextualize ferritin); (6) Folate (red blood cell folate more reliable than serum for tissue stores); (7) Thyroid (TSH, free T3) — hypothyroidism reduces EPO production and causes normocytic or macrocytic anemia; (8) Comprehensive metabolic panel (LFTs, creatinine — liver and kidney disease impair hematopoiesis); (9) LDH, haptoglobin, reticulocyte count (hemolysis screen); (10) MTHFR polymorphism for patients with elevated homocysteine or history of neural tube defects.
Key interpretation pitfalls: hemoglobin A1c (HbA1c) is falsely low with hemolytic anemia, iron deficiency, and B12/folate deficiency (all reduce RBC lifespan, producing proportionally fewer glycated hemoglobin molecules). Iron deficiency in chronic inflammatory states can present with normal or mildly elevated ferritin — soluble transferrin receptor (sTfR) testing resolves this. A normal MCV (mean corpuscular volume) does not exclude mixed deficiency: concurrent iron deficiency (microcytic) + B12 deficiency (macrocytic) can produce a normal MCV with severe anemia.
If you are experiencing fatigue, brain fog, hair loss, exercise intolerance, or cold sensitivity that hasn’t been explained by standard blood work, a comprehensive functional hematology evaluation may identify the specific deficiency or inflammatory driver that has been missed. Call (810) 206-1402 to schedule a consultation with The Private Practice team.
FAQ: What is the best form of iron supplement and how should I take it?
Iron bisglycinate (ferrous glycinate, 25–90 mg elemental iron) is the best-tolerated and most bioavailable oral iron form, with significantly fewer GI side effects than ferrous sulfate. Take on an empty stomach with vitamin C 500 mg for maximum absorption. Avoid with tea, coffee, calcium supplements, and calcium-rich meals. Alternate-day dosing (every other day rather than daily) increases net absorption by 50% by preventing hepcidin rebound suppression of absorption (Moretti 2015, Blood). Liquid iron preparations (Floradix herbal iron) are gentle options for sensitive individuals. Rectal suppositories or IV iron sucrose/ferric carboxymaltose should be reserved for confirmed malabsorption, severe intolerance, or rapid repletion needs.
FAQ: Does metformin really cause B12 deficiency?
Yes — and it is significantly underdiagnosed. Metformin reduces ileal absorption of the vitamin B12-intrinsic factor complex by inhibiting calcium-dependent membrane receptors. De Jager 2010 (BMJ) — a 4-year RCT of 390 patients — showed metformin reduced serum B12 by 19% vs placebo, with 7.2% developing B12 deficiency requiring treatment. Long-term use (>5 years) and higher doses increase risk. Critically, neurological symptoms (tingling, numbness, cognitive decline) can precede hematological changes. Every patient on metformin should have B12 and methylmalonic acid checked at least annually, with methylcobalamin 1,000 mcg/day as standard prophylactic supplementation.
FAQ: What is the difference between iron deficiency and anemia of chronic disease?
Both cause fatigue and low hemoglobin, but have opposite treatment strategies. Iron deficiency anemia: caused by inadequate iron stores — treat with iron supplementation. Anemia of chronic disease (ACD): caused by hepcidin-mediated iron trapping in macrophages due to chronic inflammation — iron supplementation is ineffective and may worsen oxidative stress. Key distinguishing labs: in ACD, ferritin is normal or elevated (inflammatory marker), transferrin saturation is low, and TIBC is normal or low. In iron deficiency, ferritin is low, transferrin saturation is low, and TIBC is elevated. Soluble transferrin receptor (sTfR) is elevated in iron deficiency but not ACD. Treatment of ACD requires addressing the underlying inflammatory driver, not adding iron.
FAQ: Can B12 deficiency really cause psychiatric symptoms?
Yes — B12 deficiency is a well-documented cause of depression, anxiety, cognitive decline, psychosis, and personality changes, often preceding or occurring without anemia. The mechanisms are multiple: impaired myelin synthesis (B12-dependent methylation of myelin basic protein) causing white matter changes; reduced methylation of neurotransmitter precursors (dopamine, serotonin) due to impaired SAM production; and elevated homocysteine directly toxic to neurons via NMDA receptor excitotoxicity and oxidative damage. In a 2017 study of 202 patients hospitalized for acute psychosis, 14.3% were found to have B12 deficiency — and those treated with B12 showed significantly greater psychiatric symptom improvement than those not treated. Functional B12 testing (B12 + MMA + homocysteine) should be standard in all psychiatric evaluations.